Archives

Vivatides Therapeutics Announces Oversubscribed $54 Million Series A Financing to Accelerate Extrahepatic RNA Therapeutics Development

B Advancing next-generation RNA therapeutics beyond the liver through breakthrough delivery technologies SUZHOU, China and BOSTON, April 10, 2026 /PRNewswire/ — Vivatides Therapeutics, a global… Login to continue reading Login…

Read MoreVivatides Therapeutics Announces Oversubscribed $54 Million Series A Financing to Accelerate Extrahepatic RNA Therapeutics Development

New Survey Data Exploring Patient Experiences with Endometrial Cancer Care Presented at 2026 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer

B 70% of patients surveyed reported the burden of chemotherapy treatment was almost as great as the burden of the disease itself, and 71% would… Login to continue reading Login…

Read MoreNew Survey Data Exploring Patient Experiences with Endometrial Cancer Care Presented at 2026 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer

Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026

B MUC16 is the highest-expressing ADC target in ovarian cancer, at least two-fold higher than other emerging targets MUC16 is highly and stably expressed in… Login to continue reading Login…

Read MoreWhitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026